

# Contents

<b>1 Adenosine A<sub>2A</sub> Receptors: Localization and Function .....</b>	<b>1</b>
Nicola Simola and Jadwiga Wardas	
<b>2 Allosteric Mechanisms in the Adenosine A<sub>2A</sub>-Dopamine D<sub>2</sub> Receptor Heteromer .....</b>	<b>27</b>
Sergi Ferré, Gemma Navarro, Jordi Bonaventura, Estefanía Moreno, Nora D. Volkow, Carme Lluís and Vicent Casadó	
<b>3 Adenosine A<sub>2A</sub> Receptor Antagonists in Drug Development .....</b>	<b>39</b>
Christa E. Müller	
<b>4 Adenosine A<sub>2A</sub> Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease .....</b>	<b>57</b>
Maria J. Diógenes, Joaquim A. Ribeiro and Ana M. Sebastião	
<b>5 Role of Adenosine A<sub>2A</sub> Receptors in the Control of Neuroinflammation—Relevance for Parkinson's Disease .....</b>	<b>81</b>
Catarina Gomes, Jimmy George, Jiang-Fan Chen and Rodrigo A. Cunha	
<b>6 Purines in Parkinson's: Adenosine A<sub>2A</sub> Receptors and Urate as Targets for Neuroprotection .....</b>	<b>101</b>
Rachit Bakshi, Robert Logan and Michael A. Schwarzschild	
<b>7 Adenosine A<sub>2A</sub> Receptor Antagonists as Drugs for Symptomatic Control of Parkinson's Disease in Preclinical Studies .....</b>	<b>127</b>
Annalisa Pinna	

<b>8 Dopamine/Adenosine Interactions Related to Tremor in Animal Models of Parkinsonism .....</b>	<b>149</b>
John D. Salamone, Samantha J. Podurgiel, Lauren L. Long, Eric J. Nunes and Mercè Correa	
<b>9 Adenosine A<sub>2A</sub> Receptor Antagonists in L-DOPA-Induced Motor Fluctuations.....</b>	<b>163</b>
Giulia Costa and Micaela Morelli	
<b>10 Adenosine A<sub>2A</sub> Receptor-Mediated Control of Non-Motor Functions in Parkinson's Disease .....</b>	<b>183</b>
Rui Daniel Prediger, Filipe Carvalho Matheus, Paulo Alexandre de Oliveira, Daniel Rial, Morgana Moretti, Ana Cristina Guerra de Souza, Aderbal Silva Aguiar and Rodrigo A. Cunha	
<b>11 Imaging Studies with A<sub>2A</sub> Receptor Antagonists .....</b>	<b>207</b>
Adriana Alexandre S. Tavares, Olivier Barret, John P. Seibyl and Gilles D. Tamagnan	
<b>12 Caffeine and Neuroprotection in Parkinson's Disease .....</b>	<b>233</b>
Filipe B. Rodrigues, Daniel Caldeira, Joaquim J. Ferreira and João Costa	
<b>13 The Story of Istradefylline—The First Approved A<sub>2A</sub> Antagonist for the Treatment of Parkinson's Disease .....</b>	<b>273</b>
Akihisa Mori, Peter LeWitt and Peter Jenner	
<b>14 Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease .....</b>	<b>291</b>
Emmanuelle Pourcher and Robert A. Hauser	
<b>15 Adenosinergic Regulation of Sleep–Wake Behavior in the Basal Ganglia.....</b>	<b>309</b>
Michael Lazarus and Yoshihiro Urade	
<b>Index.....</b>	<b>327</b>

The Adenosinergic System

A Non-Dopaminergic Target in Parkinson's Disease

Morelli, M.; Simola, N.; Wardas, J. (Eds.)

2015, XII, 337 p. 41 illus., 31 illus. in color., Hardcover

ISBN: 978-3-319-20272-3